ArticlePreventive medicine reports2025
COVID-19 symptoms associated with smoking and vaping tobacco and cannabis: A cross-sectional analysis.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Characterize symptoms observed among people using nicotine and/or cannabis compared to non-users using an institutional respiratory illness symptom checker. Methods: Cross-sectional study (April 2020-August 2021) using University of California San Francisco (UCSF) COVID-19 & Flu Symptom Checker online self-triage tool measuring current tobacco and cannabis use, symptom prevalence and associations with self-reported severe dyspnea, using multivariable logistic regression. Results: Excluding those with emergent symptoms requiring immediate medical evaluation, of 10,904 patients, 729 (6.7%) self-reported current nicotine or cannabis use. People smoking and/or vaporizing nicotine or cannabis reported constitutional, ear/nose and throat, respiratory, and gastrointestinal symptoms more frequently than non-users. Current vaping (aOR = 1.89, 95% CI 1.23, 2.81) and co-use of nicotine/cannabis (aOR = 2.00, 95% CI 1.26, 3.09) were associated with higher odds of dyspnea, adjusting for comorbidities and demographic factors. Conclusion: People using nicotine or cannabis products had increased frequencies of self-reported COVID-19 symptoms and dyspnea. Current vaporizer use may not be associated with a difference in self-reported respiratory symptoms compared to smoking tobacco. Including tobacco and cannabis use in symptom checkers may enhance risk stratification and clinical decision-making during future respiratory virus outbreaks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.